SG11201907715YA - Antigen receptors and uses thereof - Google Patents

Antigen receptors and uses thereof

Info

Publication number
SG11201907715YA
SG11201907715YA SG11201907715YA SG11201907715YA SG11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA
Authority
SG
Singapore
Prior art keywords
mainz
der
international
antigen receptors
pct
Prior art date
Application number
SG11201907715YA
Other languages
English (en)
Inventor
Ralf Holger VOSS
Ugur Sahin
Petra Simon
Matthias Birtel
Janina Caspar
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Tron – Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell & Gene Therapies Gmbh, Tron – Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of SG11201907715YA publication Critical patent/SG11201907715YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/30—Mixture of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201907715YA 2017-03-15 2018-03-14 Antigen receptors and uses thereof SG11201907715YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/056086 WO2018166589A1 (fr) 2017-03-15 2017-03-15 Récepteurs d'antigènes et leurs utilisations
PCT/EP2018/056399 WO2018167151A1 (fr) 2017-03-15 2018-03-14 Récepteurs d'antigènes et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11201907715YA true SG11201907715YA (en) 2019-09-27

Family

ID=58360981

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907715YA SG11201907715YA (en) 2017-03-15 2018-03-14 Antigen receptors and uses thereof

Country Status (15)

Country Link
US (1) US11702631B2 (fr)
EP (1) EP3596113B1 (fr)
JP (1) JP7073417B2 (fr)
KR (1) KR102396925B1 (fr)
CN (1) CN110621693B (fr)
AU (1) AU2018234068B2 (fr)
BR (1) BR112019018705A2 (fr)
CA (1) CA3054253A1 (fr)
ES (1) ES2886189T3 (fr)
IL (1) IL269213B2 (fr)
MX (1) MX2019010941A (fr)
NZ (1) NZ756383A (fr)
SG (1) SG11201907715YA (fr)
WO (2) WO2018166589A1 (fr)
ZA (1) ZA201905441B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023078431A1 (fr) * 2021-11-05 2023-05-11 清华大学 Récepteur de lymphocyte t synthétique et récepteur d'antigène se liant spécifiquement à la mésothéline et leur utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409577A (en) 1966-07-06 1968-11-05 Owens Corning Fiberglass Corp Method of detackifying tacky resins
ATE370967T1 (de) * 1998-10-21 2007-09-15 Altor Bioscience Corp Polyspezifische bindemoleküle und deren verwendung
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT2160401E (pt) * 2007-05-11 2014-10-30 Altor Bioscience Corp Moléculas de fusão e variantes de il-15
EP2502934B1 (fr) * 2011-03-24 2018-01-17 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Constructions reconnaissant les antigènes à chaîne unique stabilisées par l'introduction de nouvelles liaisons disulfure
WO2016180467A1 (fr) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Renforcement de l'effet de lymphocytes t génétiquement modifiés par car, par vaccination par acide nucléique
CA2986254A1 (fr) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion
WO2017059900A1 (fr) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Récepteurs antigéniques chimériques et leurs utilisations

Also Published As

Publication number Publication date
BR112019018705A2 (pt) 2020-04-07
WO2018166589A1 (fr) 2018-09-20
KR102396925B1 (ko) 2022-05-13
JP7073417B2 (ja) 2022-05-23
IL269213A (en) 2019-11-28
NZ756383A (en) 2023-03-31
KR20190128683A (ko) 2019-11-18
JP2020509783A (ja) 2020-04-02
CA3054253A1 (fr) 2018-09-20
IL269213B1 (en) 2023-07-01
US20200063101A1 (en) 2020-02-27
MX2019010941A (es) 2019-12-19
ZA201905441B (en) 2020-11-25
ES2886189T3 (es) 2021-12-16
AU2018234068B2 (en) 2021-10-21
EP3596113B1 (fr) 2021-08-04
EP3596113A1 (fr) 2020-01-22
IL269213B2 (en) 2023-11-01
RU2019125594A (ru) 2021-04-15
AU2018234068A1 (en) 2019-09-05
WO2018167151A1 (fr) 2018-09-20
US11702631B2 (en) 2023-07-18
RU2019125594A3 (fr) 2021-06-09
CN110621693B (zh) 2024-01-12
CN110621693A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201406963RA (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201406977TA (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201805579SA (en) Recombinant igg fc multimers
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201803642WA (en) Bacteria-based protein delivery
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201907927SA (en) Binding molecules that specifically bind to tau